Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- BLUE
- Price
- 4.97
- Stock movement up
- +- (%)
- Company name
- Bluebird bio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 48.67M
- Ent value
- 448.86M
- Price/Sales
- 0.92
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -73.57%
- 3 year return
- -56.11%
- 5 year return
- -64.05%
- 10 year return
- -45.89%
Last updated: 2025-09-12
DIVIDENDS
BLUE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.92 |
| Price to Book | - |
| EV to Sales | 8.45 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 9.79M |
| EPS (TTM) | -1.55 |
| FCF per share (TTM) | -1.19 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 53.12M |
| Gross profit (TTM) | -23.10M |
| Operating income (TTM) | -316.68M |
| Net income (TTM) | -300.52M |
| EPS (TTM) | -1.55 |
| EPS (1y forward) | -5.00 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -43.49% |
| Operating margin (TTM) | -596.15% |
| Profit margin (TTM) | -565.74% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 70.65M |
| Net receivables | 14.30M |
| Total current assets | 150.81M |
| Goodwill | 5.65M |
| Intangible assets | 9.78M |
| Property, plant and equipment | 245.69M |
| Total assets | 465.06M |
| Accounts payable | 24.48M |
| Short/Current long term debt | 368.40M |
| Total current liabilities | 296.03M |
| Total liabilities | 470.84M |
| Shareholder's equity | -5.79M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -223.69M |
| Capital expenditures (TTM) | 7.33M |
| Free cash flow (TTM) | -231.02M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -64.62% |
| Return on Invested Capital | -162.00% |
| Cash Return on Invested Capital | -124.54% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.74 |
| Daily high | 5.03 |
| Daily low | 4.67 |
| Daily Volume | 0K |
| All-time high | 3017.28 |
| 1y analyst estimate | 8.00 |
| Beta | 0.36 |
| EPS (TTM) | -1.55 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| BLUE | S&P500 | |
| Current price drop from All-time high | -99.84% | -3.84% |
| Highest price drop | -99.89% | -56.47% |
| Date of highest drop | 12 May 2025 | 9 Mar 2009 |
| Avg drop from high | -62.81% | -10.99% |
| Avg time to new high | 44 days | 12 days |
| Max time to new high | 1816 days | 1805 days |
COMPANY DETAILS
Marketcap
48.67M
Marketcap category
Small-cap
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private.
Employees
248
Website
Investor relations
-
SEC filings
CEO
Nick Leschly
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner